To fulfill Neuright’s Mission, Vision, and Promise, we have created a new theragnostic platform (combining therapy and diagnostic functions) that can provide sensitive diagnosis, neuropathy therapy to promote nerve re-growth, and drug delivery. The diagnostic is our minimum viable product (MVP) and is currently under R&D optimization and preclinical validation.
Here is where we are to date, with some milestone achievements and a look to the future:
> By 2025 we expect our product to be ready to be distributed to thought leaders throughout the nation. We have completed preclinical mouse studies in models of diabetic neuropathy, and have produced human prototype devices that have been validated in humans. Our next step is a full 'first in human' study, to be conducted with partners at The Ohio State University's Wexner Medical Center.
> Neuright, Inc. has been awarded a National Science Foundation Small Business Technology Transfer (STTR) Phase 1 award of $225,000. Through this funding, the prototype MVP device has been optimized in a pre-clinical model to then move into human.
> With $25,000 from the Maine Top Gun program, we are able to put our minimum viable product into clinical trials.
> Right now we are filing to register our intellectual property and testing our prototype. A provisional patent has been submitted. Nationalization phase began in Nov 2022
> We have received more than $350,000 in non-diluted grant funding to date. This funding has allowed us to take our product from the bench, bring it through customer-discovery market research, and create our company.
